FY2025 EPS Estimates for Codexis Raised by Cantor Fitzgerald

Codexis, Inc. (NASDAQ:CDXS) – Analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for shares of Codexis in a research note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of ($0.49) for the year, up from their previous estimate of ($0.51). Cantor Fitzgerald has a “Overweight” rating and a $11.00 price target on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The company had revenue of $21.46 million during the quarter, compared to analysts’ expectations of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%.

Codexis Price Performance

CDXS stock opened at $2.73 on Thursday. The firm has a 50 day moving average of $4.42 and a 200-day moving average of $3.96. The firm has a market capitalization of $226.15 million, a P/E ratio of -3.14 and a beta of 2.12. Codexis has a 12 month low of $2.48 and a 12 month high of $6.08. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39.

Institutional Investors Weigh In On Codexis

A number of institutional investors and hedge funds have recently made changes to their positions in the business. CenterBook Partners LP purchased a new position in shares of Codexis during the fourth quarter worth about $4,688,000. Tallon Kerry Patrick purchased a new stake in shares of Codexis during the 4th quarter valued at $2,018,000. Vanguard Group Inc. lifted its holdings in shares of Codexis by 7.5% during the 4th quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company’s stock worth $21,292,000 after acquiring an additional 311,082 shares during the last quarter. Telemark Asset Management LLC grew its position in Codexis by 11.3% in the fourth quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company’s stock worth $14,310,000 after acquiring an additional 303,589 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its position in Codexis by 18.6% during the fourth quarter. Nuveen Asset Management LLC now owns 1,812,345 shares of the biotechnology company’s stock valued at $8,645,000 after purchasing an additional 283,760 shares in the last quarter. Hedge funds and other institutional investors own 78.54% of the company’s stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.